Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zonghui Hu

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Lancet (London, England)|August 19, 2014
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trialLee-Jah Chang, Kimberly A Dowd, Floreliz H Mendoza, et al.
NPJ Vaccines|December 22, 2017
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trialAdam D DeZure, Emily E Coates, Zonghui Hu, et al.
Lancet (London, England)|December 27, 2014
Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trialHannah Kibuuka, Nina M Berkowitz, Monica Millard, et al.
Lancet (London, England)|April 26, 2026
Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trialLaura C Steinhardt, Titus K Kwambai, Martina Oneko, et al.
The New England Journal of Medicine|November 27, 2014
Chimpanzee Adenovirus Vector Ebola VaccineJulie E Ledgerwood, Adam D DeZure, Daphne A Stanley, et al.
The Lancet. Infectious Diseases|August 17, 2024
Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trialsHalimatou Diawara, Sara A Healy, Agnes Mwakingwe-Omari, et al.
The New England Journal of Medicine|November 1, 2022
Safety and Efficacy of a Monoclonal Antibody against Malaria in MaliKassoum Kayentao, Aissata Ongoiba, Anne C Preston, et al.
Plos Medicine|January 25, 2018
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adultsMartin R Gaudinski, Emily E Coates, Katherine V Houser, et al.
The Lancet. Infectious Diseases|November 21, 2021
Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trialMahamadou S Sissoko, Sara A Healy, Abdoulaye Katile, et al.
Nature Medicine|June 3, 2025
Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trialJeff Skinner, Kassoum Kayentao, Aissata Ongoiba, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Lancet (London, England)|August 19, 2014
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trialLee-Jah Chang, Kimberly A Dowd, Floreliz H Mendoza, et al.
NPJ Vaccines|December 22, 2017
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trialAdam D DeZure, Emily E Coates, Zonghui Hu, et al.
Lancet (London, England)|December 27, 2014
Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trialHannah Kibuuka, Nina M Berkowitz, Monica Millard, et al.
Lancet (London, England)|April 26, 2026
Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trialLaura C Steinhardt, Titus K Kwambai, Martina Oneko, et al.
The New England Journal of Medicine|November 27, 2014
Chimpanzee Adenovirus Vector Ebola VaccineJulie E Ledgerwood, Adam D DeZure, Daphne A Stanley, et al.
The Lancet. Infectious Diseases|August 17, 2024
Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trialsHalimatou Diawara, Sara A Healy, Agnes Mwakingwe-Omari, et al.
The New England Journal of Medicine|November 1, 2022
Safety and Efficacy of a Monoclonal Antibody against Malaria in MaliKassoum Kayentao, Aissata Ongoiba, Anne C Preston, et al.
Plos Medicine|January 25, 2018
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adultsMartin R Gaudinski, Emily E Coates, Katherine V Houser, et al.
The Lancet. Infectious Diseases|November 21, 2021
Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trialMahamadou S Sissoko, Sara A Healy, Abdoulaye Katile, et al.
Nature Medicine|June 3, 2025
Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trialJeff Skinner, Kassoum Kayentao, Aissata Ongoiba, et al.
Pageof 8